COVID-19 threw two strikes at the Extremities Market in Q2 with elective procedure shutdowns and stay-at-home orders affecting trauma volumes, but in the end, it was a whole new ballgame.
The Extremities Market had two strikes against it during Q220 related to the COVID-19 pandemic. The first strike was a fastball thrown from US states, shutting down elective procedures early in the quarter. The second strike was a slider of overall trauma injury volumes declining as a result of pandemic-related stay-at-home orders. As a result, US Extremities dropped -25.0% in Q220, according to SmartTRAK Financial Dashboard. But, with states resuming elective procedures mid-quarter, Extremities wasn’t totally out of the game. Here are some highlights from the quarter ...
Among the many topics covered in the comprehensive Q220 Extremities Market Recap* are:
- Complete Extremities Market Overview
- Extremities Fixation: Improvement begins as COVID Restrictions Lift
- Shoulders: Signs of Recovery
- COVID-19 Doesn’t Hinder Trauma & Extremities M&A Activity
- Q220 Regulatory Highlights
Despite the downturn due to the COVID-19 impact, the trauma & extremities segment saw some M&A activity during the second quarter. Conventus Orthopaedics* acquired* Flower Orthopedics in May 2020. The acquisition helps to expand Conventus’ footprint in the orthopedics space as Flower is known for its sterile packaged extremities sets, allograft kits and diabetic wound kits ...